Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Shares Outstanding (Weighted Average) (2016 - 2025)

Coherus Oncology's Shares Outstanding (Weighted Average) history spans 12 years, with the latest figure at $117.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 2.26% year-over-year to $117.1 million; the TTM value through Dec 2025 reached $117.1 million, up 2.26%, while the annual FY2025 figure was $117.1 million, 2.26% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $117.1 million at Coherus Oncology, up from $116.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $117.1 million in Q4 2025 and bottomed at $72.8 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $88.8 million (2023), against an average of $94.5 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) dropped 1.6% in 2022 before it soared 42.24% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $75.4 million in 2021, then rose by 2.89% to $77.6 million in 2022, then rose by 21.3% to $94.2 million in 2023, then rose by 21.65% to $114.6 million in 2024, then increased by 2.26% to $117.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Shares Outstanding (Weighted Average) are $117.1 million (Q4 2025), $116.1 million (Q3 2025), and $116.0 million (Q2 2025).